Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I and Phase III trial of a Haemophilus influenzae type b conjugate vaccine
CTR20192322Phase 3Terminated
- Sponsor
- Liaoning Chengda Biotechnology Co., Ltd.
- Start
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Haemophilus b conjugate vaccine in Haemophilus influenzae type b invasive infection (Hib), sponsored by Liaoning Chengda Biotechnology Co., Ltd.. Started Dec 2019; status: terminated.
02
Drugs
Haemophilus b conjugate vaccine
03
Conditions
Haemophilus influenzae type b invasive infection (Hib)
Beyond the preview
Go deeper on CTR20192322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192322.